What are the targets of Mobotinib?

Mobocertinib (Mobocertinib) is a targeted therapy designed to treat non-small cell lung cancer (NSCLC) that carries specific genetic mutations. Its mechanism of action mainly inhibits the growth and reproduction of cancer cells by targeting specific molecular targets.

Mobotinib's main target is the exon 20 insertion mutation of the epidermal growth factor receptor (EGFR) gene. This mutation leads to abnormal activation of EGFR, which promotes the rapid growth and division of cancer cells. Traditional EGFR inhibitors have limited effect on this specific mutation, while mobosetinib (mobosetinib) is specifically designed to inhibit EGFR carrying this mutation, blocking its signaling pathway, thereby effectively inhibiting tumor progression.

Mobotinib inhibits the kinase activity of EGFR by binding to its kinase domain. EGFRAbnormal activation of the kinase domain is one of the key drivers of various cancers, especially non-small cell lung cancer. By inhibiting this kinase domain, Mobotinib can effectively block EGFR-mediated signaling and reduce cancer cell proliferation and survival. This highly selective mechanism of action gives Mobotinib a unique advantage in the treatment of patients with NSCLC patients with EGFRexon20insertion mutations.

In addition to directly targeting the EGFRkinase domain, mobosetinib also achieves comprehensive inhibition of cancer cells by inhibiting multiple signaling pathways downstream of EGFR, such as the PI3K/AKT and MAPK pathways. Continuous activation of EGFR signaling often triggers overactivity of these downstream pathways, leading to abnormal growth of cancer cells. By inhibiting these pathways, Mobotinib can further enhance its inhibitory effect on cancer cells.

Mobotinib has high selectivity and mainly targets cancer cells carrying EGFR exon20 insertion mutations, while having less impact on normal cells. This selective targeting helps reduce drug toxicity and improve treatment safety. In contrast, traditional chemotherapy drugs often lack this selectivity and can cause more side effects and damage to normal cells.